(A) Frequency of monocytes (P = 0.007, FDR = 0.007) and DCs (P = 0.004, FDR = 0.007) with respect to total myeloid cells among the LC and control cohorts. (B) Frequency of classical (P nonsignificant), intermediate (P nonsignificant), and nonclassical (P = 0.006, FDR = 0.030) monocytes with respect to total monocytes among the LC and control cohorts. (C) Frequency of pDCs (P = 0.043, FDR = 0.071), cDCs (P = 0.034, FDR = 0.071), and CD123^– CD11c^– DCs (P nonsignificant) with respect to total DCs in the LC and control cohorts. (D) Frequency of cluster 7 with respect to total cDCs among the LC and control cohorts (P = 0.002, FDR = 0.014). (E) Frequency of cluster 11 with respect to total classical monocytes in the LC and control cohorts (P< 0.001, FDR = 0.001). (F) MFI fold-change (FC) of CD169, CD38, CCR6, CCR7, CCR5, CXCR3, and CXCR5 in the LC and control cohorts in each of the myeloid cell populations. *P < 0.05, FDR < 0.05. The frequency of each cluster and the MFI of the different markers was compared between the LC and control cohorts using linear regression models adjusted for SARS-CoV-2 antigen exposure, sex, and age as covariates. In all analyses, LC group, n = 98; control group, n = 18. Each dot represents an individual, and median and IQR values are indicated. P values less than 0.05 were considered statistically significant and adjusted for multiple testing using FDR.